We also focused on the impact of EGFR gene copy number on the survival prognosis of NSCLC patients and TKI-like drugs by in-depth analysis of EGFR abnormalities (including mutations, structural variants, and copy number alterations in NSCLC). This evidence concerns the gene EGFR and non-small cell lung carcinoma.